子宫内膜癌前哨淋巴结活检:美国妇科肿瘤医师的实践模式
该研究为无对照组的观察性研究,以美国妇科肿瘤学会活跃会员为对象开展在线调查,1216名会员中318人完成问卷。82.7%的受访者为子宫内膜癌分期行前哨淋巴结取样,吲哚菁绿作为示踪剂(97.3%)和宫颈注射(100%)获广泛一致应用,但注射深度等技术细节及高危组织学、无显影时是否补做淋巴结清扫等决策存在差异,部分决策证据有限且偏离现行指南。
要点
- 82.7%的受访者为子宫内膜癌分期行前哨淋巴结取样。
- 97.3%使用吲哚菁绿作为淋巴示踪剂,100%经宫颈注射。
- 仅17.9%的受访者用冰冻切片和/或触压制片评估前哨淋巴结。
核心结论
- 尽管前哨淋巴结注射与活检在子宫内膜癌中的应用日益增多,但本次调查所采样的医师之间实践模式差异相当大,部分决策基于有限证据,某些情况下偏离现行已发表指南。
研究设计与样本
- 观察性研究,无对照组。
- 研究对象为妇科肿瘤学会(Society of Gynecologic Oncology)的活跃会员。
- 经机构审查委员会批准后,通过电子邮件联系会员并以匿名方式采集答案,使用REDCap收集研究数据。
- 1216名在册会员中318人完成在线调查。
主要发现
- 多数受访者(82.7%)为子宫内膜癌分期行前哨淋巴结取样。
- 绝大多数受访者一致采用前哨淋巴结取样的多数技术环节,包括选择吲哚菁绿作为淋巴示踪剂(97.3%)及其经宫颈注射(100%)。
- 其他技术环节如注射深度在受访者之间存在差异。
- 50.9%的受访者行子宫冰冻切片术中评估,但仅17.9%通过冰冻切片和/或触压制片评估前哨淋巴结。
- 部分受访者的做法基于有限数据,包括:对高危组织学类型行前哨淋巴结注射与活检(依组织学不同由69%-75%的受访者实施)、在无前哨淋巴结显影时不行侧别特异性补做淋巴结清扫(最高达57.8%)、以及在存在淋巴结转移时的相关处理(39.9%)。
关键数值与推荐
- 82.7%的受访者为子宫内膜癌分期行前哨淋巴结取样。
- 97.3%的受访者选择吲哚菁绿作为淋巴示踪剂,100%经宫颈注射。
- 50.9%的受访者行子宫冰冻切片术中评估,17.9%通过冰冻切片和/或触压制片评估前哨淋巴结。
- 对高危组织学类型行前哨淋巴结注射与活检者依组织学不同为69%-75%。
- 无前哨淋巴结显影时不行侧别特异性补做淋巴结清扫者最高达57.8%,存在淋巴结转移时相关处理者为39.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分受访者的做法基于有限数据;某些决策偏离现行已发表指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To evaluate practice patterns among gynecologic oncologists with regard to sentinel lymph node injection and biopsy in endometrial cancer. DESIGN: An observational study with no control group. SETTING AND PATIENTS: Active members of the Society of Gynecologic Oncology. INTERVENTIONS: After institutional review board approval, we performed an online survey among active members of the Society of Gynecologic Oncology. Members were contacted via e-mail and their answers anonymously captured. Study data were collected using REDCap (REDCap developed by Vanderbilt University, Nashville TN). MEASUREMENTS AND MAIN RESULTS: Three hundred eighteen of 1216 listed members completed the online survey. The majority of respondents (82.7%) perform sentinel lymph node sampling for endometrial cancer staging. Most technical aspects of sentinel lymph node sampling were consistently applied by the vast majority of respondents, including the choice of indocyanine green as a lymphatic tracer (97.3%) and its injection into the cervix (100%). Other technical aspects of sentinel lymph node sampling, such as the depth of injection, varied among respondents. Although 50.9% of the respondents perform an intraoperative assessment of the uterus by frozen section, only 17.9% assess sentinel lymph nodes by frozen section and/or touch prep. Some of the respondents' approaches are based on limited data, including (1) the use of sentinel lymph node injection and biopsy for high-risk histologies (performed by 69%-75% of the respondents dependent on the histology), (2) omitting side-specific completion lymphadenectomy in the absence of sentinel node mapping (in up to 57.8%), or (3) when lymph node metastases are present (in 39.9%). CONCLUSION: In summary, despite the growing use of sentinel lymph node injection and biopsy in endometrial cancer, practice patterns vary considerably among providers sampled by this survey. Some of the decisions are based on limited evidence and, in some instances, deviate from current published guidelines.
引用
- Renz M, Diver E, English D, et al. Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States. J Minim Invasive Gynecol. 2019. PMID: 30980995. doi:10.1016/j.jmig.2019.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。